Search Results for "Where To Buy Pirfenidone"

01:17 EDT 25th May 2016 | BioPortfolio

Matching Channels


Matching News

Boehringer begins trial to assess OFEV with pirfenidone in IPF patients

Germany's Boehringer Ingelheim has started a new 12-week multinational trial to evaluate the safety, tolerability and pharmacokinetics (PK) of add-on treatment with pirfenidone to background therapy w...

Trial of Ofev and pirfenidone in IPF starts

Initiation of first multinational study to evaluate safety of OFEV® (nintedanib) with add-on of pirfenidone in patients with IPF

Pharmacologic Treatment of Idiopathic Pulmonary Fibrosis

What questions remain about the recently approved medications for the treatment of idiopathic pulmonary fibrosis -- pirfenidone and nintedanib. Current Opinion in Pulmonary Medicine

First Multinational Study Initiated to Evaluate OFEV® (nintedanib) with Add-on of pirfenidone in the Treatment of Idiopathic Pulmonary Fibrosis

RIDGEFIELD, Conn., Dec. 14, 2015 /PRNewswire/ -- Boehringer Ingelheim Pharmaceuticals, Inc. today announced the initiation of a new 12-week study ( Identifier: NCT02579603) to a...

Prothena Announces Appointment of Chief Commercial Officer

DUBLIN, Ireland, Feb. 24, 2016 (GLOBE NEWSWIRE) -- Prothena Corporation plc (NASDAQ:PRTA), a late-stage clinical biotechnology company focused on the discovery, development and commercializatio...

Synairgen PLC and why the market is not the best arbiter of value

If the market worked as perfectly as its more rabid advocates insist, we wouldn’t have attractive anomalies such as Synairgen plc (LON:SNG). Its shares are trading at a fraction of what would be c...

Matching PubMed Articles

Efficacy of pirfenidone and disease severity of idiopathic pulmonary fibrosis: Extended analysis of phase III trial in Japan.

A phase III clinical trial of pirfenidone in patients with idiopathic pulmonary fibrosis (IPF) in Japan has revealed that pirfenidone attenuated the decline in vital capacity (VC) and improved progres...

All-case post-marketing surveillance of 1371 patients treated with pirfenidone for idiopathic pulmonary fibrosis.

Idiopathic pulmonary fibrosis (IPF) is a chronic fibrotic lung disease with a median survival of 2-5 years and limited treatment options. In 2008, pirfenidone became the first drug to be approved for ...

A safety evaluation of pirfenidone for the treatment of idiopathic pulmonary fibrosis.

Pirfenidone is a novel oral anti-fibrotic agent approved for the treatment of idiopathic pulmonary fibrosis (IPF). Since IPF is a chronic and progressive disease most commonly encountered in an older ...

Therapeutic advances in Idiopathic Pulmonary Fibrosis.

Idiopathic pulmonary fibrosis (IPF) is a primary lung disorder that scars distal airspaces and has a prognosis similar to many aggressive cancers. After decades of failed clinical trials, two drugs (n...

Risk factors for acute exacerbation of idiopathic pulmonary fibrosis - Extended analysis of pirfenidone trial in Japan.

Acute exacerbation of idiopathic pulmonary fibrosis (AE-IPF) is a lifethreatening event and one of the important endpoints in clinical trials involving IPF. Despite this, there has been little evaluat...

Search Whole site using Google

Quick Search
Advertisement Advertisement